Waksal H W
ImClone Systems Incorporated, New York, NY, USA.
Cancer Metastasis Rev. 1999;18(4):427-36. doi: 10.1023/a:1006302101468.
Recent technological advances, together with the discovery of the important role many growth factors play in modulating cell proliferation and differentiation, have led to the development of novel therapeutic agents for the treatment of cancer. In particular, advances in hybridoma technology and molecular engineering have permitted the development of humanized or chimeric monoclonal antibodies capable of interfering with growth factor signaling pathways. One promising target of interest is the epidermal growth factor receptor (EGFr), which is activated by the ligands EGF and TGF-alpha. This ligand receptor interaction plays a crucial role in the growth and survival of many human cancers. A chimeric (human/mouse) monoclonal antibody p6tuximab (IMC-C225) targets the EGFr and has potential clinical value as an anticancer agent.
近期的技术进步，以及许多生长因子在调节细胞增殖和分化中所起重要作用的发现，促使了用于治疗癌症的新型治疗药物的研发。特别是，杂交瘤技术和分子工程学的进展使得能够开发出能够干扰生长因子信号通路的人源化或嵌合单克隆抗体。一个有前景的感兴趣靶点是表皮生长因子受体（EGFr），它由配体表皮生长因子（EGF）和转化生长因子α（TGF-α）激活。这种配体-受体相互作用在许多人类癌症的生长和存活中起着关键作用。一种嵌合（人/鼠）单克隆抗体西妥昔单抗（IMC-C225）靶向EGFr，作为一种抗癌药物具有潜在的临床价值。
